Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
Open Access
- 4 January 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1097612
Abstract
Aims: As metabolic remodeling is a pathological characteristic in type 2 diabetes (T2D), we investigate the roles of newly developed long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide and liraglutide on metabolic remodeling in patients with recent-onset T2D.Methods: We recruited 52 cases of T2D and 28 control cases in this study. In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide. Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).Results: We identified 198 metabolites that were differentially expressed in the patients with T2D, compared to the control group, in which 23 metabolites were significantly associated with fasting plasma glucose. Compared to pre-treatment, a total of 46 and 45 differentially regulated metabolites were identified after treatments with dulaglutide and liraglutide, respectively, in which the most differentially regulated metabolites belong to glycerophospholipids. Furthermore, a longitudinal integration analysis concurrent with diabetes case-control status revealed that metabolic pathways, such as the insulin resistance pathway and type 2 diabetes mellitus, were enriched after dulaglutide and liraglutide treatments. Proteins such as GLP-1R, GNAS, and GCG were speculated as potential targets of dulaglutide and liraglutide.Conclusions: In total, a metabolic change in lipids existed in the early stage of T2D was ameliorated after the treatments of GLP-1RAs. In addition to similar effects on improving glycemic control, remodeling of glycerophospholipid metabolism was identified as a signature of dulaglutide and liraglutide treatments.Keywords
This publication has 50 references indexed in Scilit:
- Plasma Lysophosphatidylcholine Levels Are Reduced in Obesity and Type 2 DiabetesPLOS ONE, 2012
- Emerging Perspectives on Essential Amino Acid Metabolism in Obesity and the Insulin-Resistant StateAdvances in Nutrition, 2011
- Metabolite profiles and the risk of developing diabetesNature Medicine, 2011
- Apoptosis in Heart Failure - The Role of the .BETA.-Adrenergic Receptor-Mediated Signaling Pathway and p53-Mediated Signaling Pathway in the Apoptosis of Cardiomyocytes -Circulation Journal, 2011
- Plasma Metabolomic Profiles Reflective of Glucose Homeostasis in Non-Diabetic and Type 2 Diabetic Obese African-American WomenPLOS ONE, 2010
- Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traitsMetabolomics, 2010
- Metabolism and atherogenic disease association of lysophosphatidylcholineAtherosclerosis, 2010
- Lysophosphatidylcholine Activates Adipocyte Glucose Uptake and Lowers Blood Glucose Levels in Murine Models of DiabetesJournal of Biological Chemistry, 2009
- A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and Contributes to Insulin ResistanceCell Metabolism, 2009
- Link between obesity and type 2 diabetesBest Practice & Research Clinical Endocrinology & Metabolism, 2005